Effect of Dietary Ceramide and Glucosylceramide on the Alleviation of Experimental Inflammatory Bowel Disease in Mice
論文ID: ess22169
この記事には本公開記事があります。
詳細
論文ID: ess22169
Ceramide prepared from glucosylceramide (GlcCer) with Gluceribacter canis NATH-2371T was administrated to inflammatory bowel disease (IBD) model mice. Dietary ceramide significantly suppressed the decrease in final body weight, and the increase in the disease activity index and myeloperoxidase activity more greatly than GlcCer in IBD mice. Intestinal microbiome profiles were found to be altered in IBD mice, but ceramide counteracted the changes. These results suggest that dietary plant-based ceramide may alleviate symptoms of IBD in mice.
